Heilig-Geist-Hospital, Bensheim, Germany.
University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
World J Urol. 2021 Jan;39(1):89-95. doi: 10.1007/s00345-020-03157-4. Epub 2020 Mar 31.
To investigate the predictors of recurrence and of de novo incontinence in patients treated by transurethral incision or resection for vesico-urethral anastomotic stenosis (VUAS) after radical prostatectomy.
All patients undergoing endoscopic treatment for VUAS between March 2009 and October 2016 were identified in our multi-institutional database. Digital chart reviews were performed and patients contacted for follow-up. Recurrence was defined as any need for further instrumentation or surgery, and de-novo-incontinence as patient-reported outcome.
Of 103 patients undergoing endoscopic VUAS treatment, 67 (65%) underwent transurethral resection (TR) and 36 (35%) transurethral incision (TI). TI was performed more frequently as primary treatment compared to TR (58% vs. 37%; p = 0.041). Primary and repeated treatment was performed in 46 (45%) and 57 patients (55%), respectively. Overall, 38 patients (37%) had a history of radiation therapy. There was no difference in time to recurrence for primary vs repeat VUAS treatment, previous vs no radiation, TR compared to TI (all p > 0.08). Regarding treatment success, no difference was found for primary vs. repeat VUAS treatment (50% vs. 37%), previous radiation vs. no radiation (42% vs. 43%), and TR vs. TI (37% vs. 53%; all p ≥ 0.1). Postoperative de novo incontinence was more common after TI vs. TR (31% vs. 12%; p = 0.032), no difference was observed for previous radiation therapy vs. no radiation therapy (18% vs. 18%; p > 0.9) or primary vs. repeat VUAS treatment (22% vs. 16%; p = 0.5).
VUAS recurrence after endoscopic treatment is not predictable. Endoscopic treatment with TI showed a higher risk for de novo incontinence than TR, and previous irradiation and the number of treatments do not influence incontinence.
探讨经尿道切开或切除治疗根治性前列腺切除术后膀胱尿道吻合口狭窄(VUAS)后复发和新发尿失禁的预测因素。
在我们的多机构数据库中,确定了 2009 年 3 月至 2016 年 10 月期间因 VUAS 接受内镜治疗的所有患者。进行了数字图表审查并联系患者进行随访。复发定义为需要进一步的器械或手术,新发尿失禁定义为患者报告的结果。
103 例接受内镜 VUAS 治疗的患者中,67 例(65%)接受经尿道切除(TR),36 例(35%)接受经尿道切开(TI)。与 TR 相比,TI 更常作为主要治疗方法(58%比 37%;p=0.041)。46 例(45%)和 57 例(55%)患者分别接受了初次和重复治疗。总体而言,38 例(37%)有放疗史。初次与重复 VUAS 治疗、有或无放疗史、TR 与 TI 之间的复发时间无差异(所有 p>0.08)。关于治疗效果,初次与重复 VUAS 治疗(50%比 37%)、有或无放疗史(42%比 43%)、TR 与 TI(37%比 53%)之间无差异(所有 p≥0.1)。TI 后新发尿失禁较 TR 更为常见(31%比 12%;p=0.032),放疗史与无放疗史之间(18%比 18%;p>0.9)或初次与重复 VUAS 治疗之间(22%比 16%;p=0.5)无差异。
内镜治疗后 VUAS 复发不可预测。经尿道切开术治疗的 TI 比 TR 更易发生新发尿失禁,而既往照射和治疗次数并不影响尿失禁。